infection rates

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered adverse effects adverse event Arm ARMS Asymptomatic baseline Care clinical clinical benefit Clinical outcome clinical outcomes clinical trial clinically cohorts conducted coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 detect determined by double-blind effective Efficacy Enrollment evaluate exposure to finding Follow-up Frequency futility HCW HCWs Health Health care Health care worker health care workers hospital Hospitalization hospitals Hydroxychloroquine Identifier Importance incidence individual infection rate infection rates knowledge measure median median age Nasopharyngeal swab no significant difference not differ Nurses objective outcome participant Participants Patient patients with COVID-19 per day pharmacologic prophylaxis Philadelphia Physicians Placebo placebo-controlled placebo-controlled clinical trial Point polymerase chain positive result Prevent prevention Primary outcome Prophylaxis prophylaxis strategy QTc QTC prolongation Randomized randomized clinical trial receive reduce regimen Registration Relevance required respiratory Result reverse-transcriptase polymerase chain reaction risk Safety SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2–positive secondary Secondary outcomes setting severe acute respiratory syndrome Coronavirus significant difference Transmission transmission of SARS-CoV-2 Treatment Trial Trial registration Viral women worker
[DOI] 10.1001/jamainternmed.2020.6319 PMC 바로가기 [Article Type] Randomized Controlled Trial